多肽-N乙酰氨基半乳糖转移酶10在肺癌中的表达及意义

蔡翠霞; 高媛; 刘玥; 王涵多

doi:10.16098/j.issn.0529-1356.2020.02.009

PDF(8986 KB)

解剖学报 ›› 2020, Vol. 51 ›› Issue (2) : 206-210. DOI: 10.16098/j.issn.0529-1356.2020.02.009

肿瘤生物学

多肽-N乙酰氨基半乳糖转移酶10在肺癌中的表达及意义

蔡翠霞高媛刘玥王涵多*

作者信息 +

Expression of polypeptide N-acetylgalactosaminyltransferase-10 in lung cancer#br#

CAI Cui-xia GAO Yuan LIU Yue WANG Han-duo*

Author information +

文章历史 +

摘要

目的探讨检测多肽-N乙酰氨基半乳糖转移酶10（pp GalNAc-T10）单细胞技术与应用蛋白在肺癌、乳腺癌和结肠癌中的表达。方法采用免疫组织化学检测ppGalNAc-T10在110例肺癌组织、100例乳腺癌组织和110例结肠癌组织中的表达；不同的肿瘤均有10例相对应的正常组织作为对照。结果同正常肺组织相比较，ppGalNAc-T10在肺癌组织中表达较低；且ppGalNAc-T10的表达与肿瘤侵袭深度相关(P<0.01)。PpGalNAc-T10蛋白在乳腺癌和结肠癌及其相对应的正常组织的表达差异无显著性。结论 PpGalNAc-T10在肺癌中，有可能成为的1个有效标记蛋白。

Abstract

Objective The purpose of this study is to investigate the expression of the polypeptide N-acetylgalactosaminyltransferase-10(ppGalNAc-T10) protein in lung and breast and colon cancer. Methods Immunohistochemistry was used to analyse ppGalNAc-T10 expressions in 110 lung cancer tissues, 100 breast cancer tissues and 110 colon cancer tissues. Meanwhile, different cancer has 10 cases of normal tissues as control. Results The expression of ppGalNAc-T10 in normal lung tissue was higher compared with that in lung cancer organizations, and ppGalNAc-T10 positive expression was found to be significantly associated with invasion depth of tumor (P<0.01). PpGalNAc-T10 protein expression in breast and colon cancer was no significantly difference than that in non-tumor breast and colon tissue. Conclusion PpGalNAc-T10 expression is a useful marker in lung cancer.

导出引用

蔡翠霞高媛刘玥王涵多. 多肽-N乙酰氨基半乳糖转移酶10在肺癌中的表达及意义[J]. 解剖学报. 2020, 51(2): 206-210 https://doi.org/10.16098/j.issn.0529-1356.2020.02.009

CAI Cui-xia GAO Yuan LIU Yue WANG Han-duo. Expression of polypeptide N-acetylgalactosaminyltransferase-10 in lung cancer#br#[J]. Acta Anatomica Sinica. 2020, 51(2): 206-210 https://doi.org/10.16098/j.issn.0529-1356.2020.02.009

中图分类号： R735.1

参考文献

［1］ Ten Hagen KG, Fritz TA, Tabak LA, et al. All in the family: the UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferases［J］. Glycobiologyvol, 2003, 13(1): 1R-16R.

［2］ Huang MJ, Hu RH, Chou CH, et al. Knockdown of GALNT1 suppresses malignant phenotype of hepatocellular carcinoma by suppressing EGFR signaling［J］. Oncotarget, 2015, 6(8):5650-5665.

［3］ Guo JM, Chen HL, Wang GM, et al. Expression of UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase-12 in gastric and colonic cancer cell lines and in human colorectal cancer［J］. Oncology, 2004, 67(34):271-276.

［4］ Gu C, Oyama T, Osaki T, et al. Low expression of polypeptide GalNAc N-acetylgalactosaminyl transferase-3 in lung adenocarcinoma: impact on poor prognosis and early recurrence［J］. Br J Cancer, 2004, 90(2):436-442.

［5］ Wang ZQ, Bachvarova M, Morin C, et al. Role of the polypeptide N-acetylgalactosaminyltransferase 3 in ovarian cancer progression: possible implications in abnormal mucin O-glycosylation［J］. Oncotarget, 2014, 5(2):544-560.

［6］ Lina MC, Huang MJ, Liu CH, et al. GALNT2 enhances migration and invasion of oral squamous cell carcinoma by regulating EGFR glycosylation and activity［J］. Oral Oncology, 2014, 50(5):478-484.

［7］ Gao Y, Liu Z, Feng J, et al. Expression pattern of polypeptide N-acetylgalactosaminyltransferase-10 in gastric carcinoma［J］. Oncol Lett, 2013, 5(1):113-116.

［8］ Li Z, Yamada S, Wu Y, et al. Polypeptide N-acetylgalactosaminyltransferase-6 expression independently predicts poor overall survival in patients with lung adenocarcinoma after curative resection［J］. Oncotarget, 2016, 7(34): 54463-54473

［9］ Berois N, Mazal D, Ubillos L, et al. UDP-N-Acetyl-D-Galactosamine: Polypeptide N-Acetylgalactosaminyltransferase-6 as a New Immunohistochemical Breast Cancer Marker［J］. J Histochem Cytochem, 2006, 54(3): 317-328.

［10］ He H, Shen Z, Zhang H, et al. Clinical significance of polypeptide N-acetylgalactosaminyl transferase-5 (GalNAc-T5) expression in patients with gastric cancer［J］. Br J Cancer, 2014, 110(8): 2021-2029.